ERBB2 and neoplasm: Caudle et al. reported that HR−/HER2 + and HR-/HER2- patients with a poor response to NAC had worse LRRFS after BCS. Furthermore, the authors found that patients with HR + /HER2− and HR + /HER2 + subtypes had excellent LRRFS, regardless of tumor response to NAC[1].